Theriva Biologics
TOVX
23 hedge funds and large institutions have $1.61M invested in Theriva Biologics in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
5% more funds holding
Funds holding: 22 → 23 (+1)
0.01% more ownership
Funds ownership: 0.08% → 0.09% (+0.01%)
16% less capital invested
Capital invested by funds: $1.93M → $1.61M (-$317K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.06M |
| 2 |
AC
Armistice Capital
New York
|
+$529K |
| 3 |
Renaissance Technologies
New York
|
+$290K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$149K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.5K |
| 2 |
Jane Street
New York
|
-$49K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$29K |
| 4 |
VF
Virtu Financial
New York
|
-$20.4K |
| 5 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$237 | -1 | -50% |
|
TOVX Hedge Fund Activity: Q4 2018 in Review
23 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2018, worth a combined $1.61M — down 16% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TOVX positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.06M. The largest seller was Vanguard Group, cutting an estimated $89.5K.
- 23 institutional investors held Theriva Biologics (TOVX) as of Q4 2018, up from 22 in Q3 2018.
- Funds reported $1.61M of Theriva Biologics stock for Q4 2018, down 16% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q4 2018 and 6 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q4 2018 was Sabby Management, an estimated $1.06M added.
- The largest Theriva Biologics seller in Q4 2018 was Vanguard Group, an estimated $89.5K sold.
Based on aggregated 13F filings for Q4 2018.